ReviewMolecular diversity2026
"Acne vulgaris: key insights, treatment, and future prospects".
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy of Fire Needle Therapy Combined with Doxycycline Hydrochloride in the Management of Moderate-to-Severe Acne Vulgaris: A Randomized Controlled Trial.Journal of multidisciplinary healthcare · 2025Trial
- Chemical Characteristics and Antimicrobial Activity ofMolecules (Basel, Switzerland) · 2026Article
- Dissolved bubble microneedle patches for co-delivery of hydrophobic and hydrophilic drugs to improve acne vulgaris therapy.Microsystems & nanoengineering · 2025Article
- Validation of Madecassoside Synergy Significantly Enhanced Cryptotanshinone's Therapeutic Efficacy Against Acne Vulgaris.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is an immune-mediated inflammatory skin condition. It is the 8th most treated skin condition, affecting over 80% of teenagers globally. The pathophysiology of the disease is intricate and involves the interaction of multiple factors, including hyperactivation of sebaceous glands, abnormal hyperkeratinization of pilosebaceous follicles, dysbiosis of microflora, and, subsequently, immune-mediated inflammation. Due to the multifaceted nature of the disorder, a combination of different anti-acne agents is preferred. However, synthetic topical anti-acne agents such as retinol derivatives and benzoyl peroxide are often associated with common side effects such as redness, dryness, peeling, irritation, and eczema. Also, increasing cases of multidrug resistance against commonly used antibiotics further reduce the therapeutic effectiveness of the treatment and upsurge the overall expense. Many studies validate using plant extracts and secondary metabolites for treating acne. Alongside synergistic formulations, the co-delivery of synthetic and herbal agents is emerging as the latest target for developing novel and efficient acne treatments. This article summarizes the comprehensive pathophysiology of the disease, classification, and grading system evolution, along with detailed information on different FDA-approved synthetic topical and systemic anti-acne agents (retinoids, antibiotics, and diverse medications). In addition, we highlight the new investigation on several phytoconstituents and secondary metabolites for treating acne vulgaris. Finally, we have attached the details of all the ongoing clinical trials on acne therapy.
Indexed as
Identifiers
40377827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.